In humans, iscalimab, a fully human, non-depleting anti-CD40 antibody, showed its safety and capability to inhibit humoral response to vaccination and to inhibit CD154-induced B cell activation, supporting its potential interest in autoimmune diseases [109]. The gene discussed is CD40; the disease is autoimmune disease.